INHIBITORS OF p38

Abstract

The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to inhibitors of ZAP70. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

1 . A compound of the formula: 
       
         
           
           
               
               
           
         
         wherein Q 1  is selected from a phenyl or 5-6 membered aromatic heterocyclic ring system, or a 8-10 membered bicyclic ring system of aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring; 
         wherein the rings that make up Q 1  are substituted with 1 to 4 substituents, each of which is independently selected from halo; C 1 -C 3  alkyl optionally substituted with NR′ 2 , OR′, CO 2 R′ or CONR′ 2 ; o—(C 1 -C 3 )-alkyl optionally substituted with NR′ 2 , OR′, CO 2 R′ or CONR′ 2 ; NR′ 2 ; OCF 3 ; CF 3 ; NO 2 ; CO 2 R′; CONHR′; SR′; S(O 2 )N(R′) 2 ; SCF 3 ; CN; N(R′)C(O)R 4 ; N(R′)C(O)OR 4 ; N(R′)C(O)C(O)R 4 ; N(R′)S(O 2 )R 4 ; N(R′)R 4 ; N(R 4 ) 2 ; OR 4 ; OC(O)R 4 ; OP(O) 3 H 2 ; N═CH—N(R′) 2 ; 3,4-methylenedioxy; —NH—C(O)O—CH 2 -4-pyridine; —NH—C(O)CH 2 -morpholine; —NH—C(O)CH 2 -piperazine; or —NH—C(O)CH 2 -pyrrolidine; 
         wherein each R′ is independently selected from hydrogen; (C 1 -C 3 )-alkyl; (C 2 -C 3 )-alkenyl or alkynyl; phenyl or phenyl substituted with 1 to 3 substituents independently selected from halo, methoxy, cyano, nitro, amino, hydroxy, methyl or ethyl; or a 5-6 membered heterocyclic ring system optionally substituted with 1 to 3 substituents independently selected from halo, methoxy, cyano, nitro, amino, hydroxy, methyl or ethyl; 
         wherein each R is independently selected from hydrogen, —R 2 , —N(R 2 ) 2 , —OR 2 , SR 2 , —C(O)—N(R 2 ) 2 , —S(O 2 )—N(R 2 ) 2 , —C(O)—OR 2  or —C(O)R 2  wherein two adjacent R are optionally bound to one another and, together with each Y to which they are respectively bound, form a 4-8 membered carbocyclic or heterocyclic ring; 
         wherein each R 2  is independently selected from hydrogen; or (C 1 -C 3 )-alkyl or (C 2 -C 3 )-alkenyl, each optionally substituted with —N(R′) 2 , —OR′, SR′, —O—C(O)—N(R′) 2 , —C(O)—N(R′) 2 , —S(O 2 )—N(R′) 2 , —C(O)—OR′, NHSO 2 R 4 , NHSO 2 R 3 , —C(O)N(R′)(R 3 ), NHC(O)R 4 , —N(R′)(R 3 ), —N(R′)(R 4 ), —C(O)R 3 , —C(O)N(R′)(R 4 ), —N(R 4 ) 2 , —C(O)N═C(NH) 2  or R 3 ; 
         wherein each R 3  is independently selected from 5-8 membered aromatic or non-aromatic carbocyclic or heterocyclic ring systems each optionally substituted with R′, R 4 , —C(O)R′, —C(O)R 4 , —C(O)OR 4  or —K; or an 8-10 membered bicyclic ring system of aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring each optionally substituted with R′, R 4 , —C(O)R′, —C(O)R 4 , —C(O)OR 4  or —K; 
         wherein each R 4  is independently selected from R′; (C 1 -C 7 )-straight or branched alkyl optionally substituted with R′, N(R′) 2 , OR′, CO 2 R′, CON(R′) 2 , SO 2 N(R′) 2  or SO 2 N(R 5 ) 2 ; or a 5-6 membered carbocyclic or heterocyclic ring system optionally substituted with N(R′) 2 , OR′, CO 2 R′, CON(R′) 2 , SO 2 N(R′) 2  or SO 2 N(R 5 ) 2 ; 
         wherein each R 5  is independently selected from hydrogen, (C 1 -C 3 )-alkyl, or (C 2 -C 3 )-alkenyl; each optionally substituted with —N(R′) 2 , —OR′, SR′, —C(O)—N(R′) 2 , —S(O 2 )—N(R′) 2 , —C(O)—OR′, NH—S(O 2 )(R′), NHSO 2 R 6 , —C(O)N(R′)(R 6 ), NHC(O)R′, —N(R′)(R 6 ), —C(O)R 6 , —C(O)N═C(NH) 2  or R 6 ; 
         wherein each R 6  is independently selected from 5-8 membered aromatic or non-aromatic carbocyclic or heterocyclic ring systems each optionally substituted with R′, —C(O)R′ or —C(O)OR′; or an 8-10 membered bicyclic ring system of aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring each optionally substituted with R′, —C(O)R′ or C(O)OR′; 
         wherein R 7  is selected from H, halogen, or a (C 1 -C 3 ) straight chain or branched alkyl; 
         wherein each Y is independently selected from N or C, and wherein if either Y is N, then R or U attached to Y is a lone pair of electrons; 
         wherein Z is CH, N, C(OCH 3 ), C(CH 3 ), C(NH 2 ), C(OH) or C(F); 
         wherein each U is independently selected from R or J; 
         wherein each J is independently selected from a (C 1 -C 4 ) straight chain or branched alkyl substituted with T; 
         wherein each T is independently selected from either O(V) or N(H)(V); 
         wherein each V is independently selected from C(O)N═C(R)(N(R) 2 ), wherein the two geminal R on the nitrogen are optionally bound to one another to form a 4-8 membered carbocyclic or heterocyclic ring; 
         wherein each K is independently selected from a (C 1 -C 4 ) straight chain or branched alkyl substituted with D, or —OP(O)(OH) 2 ; 
         wherein each D is independently selected from either enantiomer of 
       
       
         
           
           
               
               
           
         
         wherein each M is independently selected from either O or NH; 
         wherein each G is independently selected from NH 2 , OH, or H; 
         wherein each R 8  is independently selected from H, OH, C(O)OH, (C 1 -C 7 )-straight or branched alkyl optionally substituted with N(R′) 2 , OR′, CO 2 R′, CON(R′) 2 , or SO 2 N(R 5 ) 2 ; or a 5-6 membered carbocyclic, heterocyclic or heteroaryl ring system optionally substituted with N(R′) 2 , OR′, CO 2 R′, CON(R′) 2 , or SO 2 N(R 5 ) 2 ; wherein G and R 8  are optionally bound to one another to form a ring. 
       
     
     
         2 . The compound according to  claim 1 , wherein Q 1  is selected from phenyl or pyridyl substituted with 1 to 3 substituents independently selected from chloro, fluoro, bromo, —CH 3 , —OCH 3 , —OH, —CF 3 , —OCF 3 , —O(CH 2 ) 2 CH 3 , NH 2 , 3,4-methylenedioxy, —N(CH 3 ) 2 , —NH—S(O) 2 -phenyl, —NH—C(O)O—CH 2 -4-pyridine, —NH—C(O)CH 2 -morpholine, —NH—C(O)CH 2 —N(CH 3 ) 2 , —NH—C(O)CH 2 -piperazine, —NH—C(O)CH 2 -pyrrolidine, —NH—C(O)C(O)-morpholine, —NH—C(O)C(O)-piperazine, —NH—C(O)C(O)-pyrrolidine, —O—C(O)CH 2 —N(CH 3 ) 2 , or —O—(CH 2 ) 2 —N(CH 3 ) 2  and wherein at least one of said substituents is in the ortho position. 
     
     
         3 . The compound according to  claim 2 , wherein Q 1  is substituted with at least two substituents, both of which are in the ortho position. 
     
     
         4 . The compound according to  claim 2 , wherein Q 1  is selected from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         5 . The compound according to  claim 4 , wherein Q 1  is selected from 2-fluoro-6-trifluoromethylphenyl, 2,6-difluorophenyl, 2,6-dichlorophenyl, 2-chloro-4-hydroxyphenyl, 2-chloro-4-aminophenyl, 2,6-dichloro-4-aminophenyl, 2,6-dichloro-3-aminophenyl, 2,6-dimethyl-4-hydroxyphenyl, 2-methoxy-3,5-dichloro-4-pyridyl, 2-chloro-4,5 methylenedioxy phenyl, or 2-chloro-4-(N-2-morpholino-acetamido)phenyl. 
     
     
         6 - 8 . (canceled) 
     
     
         9 . The compound according to  claim 1 , wherein each Y is C. 
     
     
         10 . The compound according to  claim 9 , wherein the R attached to Y is independently selected from hydrogen or methyl. 
     
     
         11 . The compound according to  claim 1 , wherein J terminates in an alcohol, amine, carboxylic acid, ester, amide, amidine or heterocycle. 
     
     
         12 . The compound according to  claim 11 , wherein J is selected from: 
       
         
           
           
               
               
           
         
       
     
     
         13 . The compound according to  claim 1  wherein K is selected from: 
       
         
           
           
               
               
           
         
       
     
     
         14 . The compound according to  claim 1 , wherein the compound is selected from any one of the following compounds: 
       
         
           
                 
                 
                 
               
                     
                 
                     
                   Cmpd 
                     
                 
                     
                   Nmbr 
                   Structure 
                 
                     
                 
                     
                   118 
                   
                     
                       
                       
                           
                           
                       
                     
                   
                 
                     
                 
                     
                   119 
                   
                     
                       
                       
                           
                           
                       
                     
                   
                 
                     
                 
                     
                   120 
                   
                     
                       
                       
                           
                           
                       
                     
                   
                 
                     
                 
                     
                   121 
                   
                     
                       
                       
                           
                           
                       
                     
                   
                 
                     
                 
                     
                   122 
                   
                     
                       
                       
                           
                           
                       
                     
                   
                 
                     
                 
                     
                   123 
                   
                     
                       
                       
                           
                           
                       
                     
                   
                 
                     
                 
                     
                   124 
                   
                     
                       
                       
                           
                           
                       
                     
                   
                 
                     
                 
                     
                   125 
                   
                     
                       
                       
                           
                           
                       
                     
                   
                 
                     
                 
             
                
                
                
                
               
               
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         15 - 17 . (canceled) 
     
     
         18 . The compound according to  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       wherein 
       
         
           
           
               
               
           
         
       
     
     
         19 . The compound according to  claim 1 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       wherein 
       
         
           
           
               
               
           
         
       
     
     
         20 . A pharmaceutical composition comprising an amount of a compound according to  claim 1  effective to inhibit p38, and a pharmaceutically acceptable carrier. 
     
     
         21 - 33 . (canceled) 
     
     
         34 . A pharmaceutical composition comprising an amount of a compound according to  claim 1  effective to inhibit ZAP70, and a pharmaceutically acceptable carrier. 
     
     
         35 - 38 . (canceled)